LPCN — Lipocine Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1535955 ·
Last close
$1.60
Market Cap
$17.72M
52W High
$12.37
52W Low
$1.36
ADV30
3,873,815
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,290,072 — -868,525 -666,192 23,196,594 2,594,151 2,034,446
Jun 2026 190,099 -1,851,290 -2,842,246 -2,622,595 23,835,361 4,979,430 2,067,957
Mar 2026 119,397 — -3,849,464 -3,671,894 25,358,166 5,015,608 2,527,843
Dec 2025 1,145,390 — -2,515,801 -2,370,084 17,005,612 5,205,842 2,528,196

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,190,794
Investing CF
$-6,146,470
Financing CF
$16,272,714
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-215,690,856
Inventory
—
Receivables
$291,164
ST Investments
$18,287,179
EBIT TTM
$-12,568,551
Pretax Income TTM
$-11,851,205
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,569,460
EBITDA
$-12,509,986
Free Cash Flow
$-6,939,857
Enterprise Value
$-10,395,095
Total Cash
$23,266,608
Total Debt
$257,807
Shares Out
11,073,439
Trailing EPS
$-1.32
Book Value
$2.35
ROE
-60.9%
ROA
-37.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,976,677 -10,371,379 -9,627,505 17,005,612 2,528,196 14,477,416 -9,760,721
Dec 2024 11,198,144 -1,155,035 8,352 22,510,501 1,512,936 20,997,565 -1,221,233
Dec 2023 -2,850,818 -17,930,957 -16,352,082 23,001,072 2,631,629 20,369,443 -11,865,991
Dec 2022 500,000 -12,119,375 -10,758,636 37,542,922 1,907,982 35,634,940 -11,968,819
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,569,460
NetIncome TTM
$-11,851,405
OpCashFlow TTM
—
Assets (Latest)
$23,835,361
Forward EPS
$-1.24

Peers — same industry

TickerNameMarket CapLastDaily %
PVCT PROVECTUS BIOPHARMACEUTICALS, INC. $17.90M $0.04 —
CELU Celularity Inc $18.53M $0.57 —
EDSA Edesa Biotech, Inc. $18.90M $1.96 —
ATOS ATOSSA THERAPEUTICS, INC. $18.96M $1.90 —
VICP Vicapsys Life Sciences, Inc. $16.19M $0.50 —

News headlines (Yahoo Finance, 1h cache)

Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
2026-11-10 13:00 · Yahoo
Lipocine: Q3 Earnings Snapshot
2026-11-05 13:34 · Yahoo
Lipocine Announces Financial Results for the Third Quarter of 2026
2026-11-05 13:00 · Yahoo
Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 13:57 · Yahoo
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
2026-10-07 14:01 · Yahoo
Lipocine stock surges 30% on Health Canada drug approval
2026-10-07 13:24 · Yahoo
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
2026-10-07 12:44 · Yahoo
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
2026-10-07 12:00 · Yahoo
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-23 16:00 · Yahoo
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.